CIK 0001454789
ATXS Astria Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing Jun 12, 2025.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
14
with a Form 4 at this company
Signals
Open-market buys and sells at Astria Therapeutics, Inc., scored.
No scored open-market trades yet. Grants, exercises and other rows are below.
Transactions
The last 14 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 11, 2025 | Sunil Agarwal director | AGrant or award Stock Option (Right to Buy)derivative | +26,550 | $0.00 | $0 | 26,550 | Jun 12, 2025 |
| Jun 11, 2025 | Fred Callori director | AGrant or award Stock Option (Right to Buy)derivative | +26,550 | $0.00 | $0 | 26,550 | Jun 12, 2025 |
| Jun 11, 2025 | Joanne T. Beck director | AGrant or award Stock Option (Right to Buy)derivative | +26,550 | $0.00 | $0 | 26,550 | Jun 12, 2025 |
| Jun 11, 2025 | Jonathan Violin director | AGrant or award Stock Option (Right to Buy)derivative | +26,550 | $0.00 | $0 | 26,550 | Jun 12, 2025 |
| Jun 11, 2025 | Anthony Gregg Lapointe director | AGrant or award Stock Option (Right to Buy)derivative | +26,550 | $0.00 | $0 | 26,550 | Jun 12, 2025 |
| Jun 11, 2025 | Michael D Kishbauch director | AGrant or award Stock Option (Right to Buy)derivative | +26,550 | $0.00 | $0 | 26,550 | Jun 12, 2025 |
| Jun 11, 2025 | Hugh M Cole director | AGrant or award Stock Option (Right to Buy)derivative | +26,550 | $0.00 | $0 | 26,550 | Jun 12, 2025 |
| Jun 11, 2025 | Kenneth Bate director | AGrant or award Stock Option (Right to Buy)derivative | +26,550 | $0.00 | $0 | 26,550 | Jun 12, 2025 |
| Mar 21, 2025 | Christopher Morabito Chief Medical Officer | AGrant or award Stock Option (Right to Buy)derivative | +262,500 | $0.00 | $0 | 262,500 | Mar 25, 2025 |
| Mar 21, 2025 | Noah Clauser Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +262,500 | $0.00 | $0 | 262,500 | Mar 25, 2025 |
| Mar 21, 2025 | Benjamin Harshbarger Chief Legal Officer | AGrant or award Stock Option (Right to Buy)derivative | +262,500 | $0.00 | $0 | 262,500 | Mar 25, 2025 |
| Mar 21, 2025 | Andrew Komjathy Chief Commercial Officer | AGrant or award Stock Option (Right to Buy)derivative | +225,000 | $0.00 | $0 | 225,000 | Mar 25, 2025 |
| Mar 21, 2025 | Andrea Matthews Chief Business Officer | AGrant or award Stock Option (Right to Buy)derivative | +262,500 | $0.00 | $0 | 262,500 | Mar 25, 2025 |
| Mar 21, 2025 | Jill C. Milne CEO and President | AGrant or award Stock Option (Right to Buy)derivative | +761,000 | $0.00 | $0 | 761,000 | Mar 25, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Sunil Agarwaldirector
- Kenneth Batedirector
- Joanne T. Beckdirector
- Fred Calloridirector
- Noah ClauserChief Financial Officer
- Hugh M Coledirector
- Benjamin HarshbargerChief Legal Officer
- Michael D Kishbauchdirector
- Andrew KomjathyChief Commercial Officer
- Anthony Gregg Lapointedirector
- Andrea MatthewsChief Business Officer
- Jill C. MilneCEO and President
- Christopher MorabitoChief Medical Officer
- Jonathan Violindirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.